J
Javier P. Gisbert
Researcher at Autonomous University of Madrid
Publications - 1076
Citations - 39753
Javier P. Gisbert is an academic researcher from Autonomous University of Madrid. The author has contributed to research in topics: Helicobacter pylori & Inflammatory bowel disease. The author has an hindex of 95, co-authored 990 publications receiving 33726 citations. Previous affiliations of Javier P. Gisbert include Services Hospital & University of Alcalá.
Papers
More filters
Journal ArticleDOI
Fourth‐line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures
Javier P. Gisbert,Manuel Castro-Fernandez,Ángeles Pérez-Aisa,Angel Cosme,Javier Molina-Infante,Luis Rodrigo,Ines Modolell,José Luis Cabriada,Jose Luis Gisbert,Eloisa Lamas,E Marcos,Xavier Calvet +11 more
TL;DR: In some cases, Helicobacter pylori infection persists even after three eradication treatments, and the need for further treatment is still considered.
Journal ArticleDOI
Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis.
Carlos Taxonera,Cristina Rodríguez,Federico Bertoletti,Luis Menchén,Julia Arribas,M Sierra,Lara Arias,Pilar Martínez-Montiel,Alba Juan Juan,Eva Iglesias,Alicia Algaba,Noemí Manceñido,Montserrat Rivero,Manuel Barreiro-de Acosta,Pilar López-Serrano,Federico Argüelles-Arias,Ana Gutiérrez,David Busquets,Javier P. Gisbert,David Olivares,Marta Calvo,Cristina Alba +21 more
TL;DR: In this real-life cohort of patients with UC, golimumab therapy was effective for inducing and maintaining clinical response and was also effective in anti-TNF–experienced patients.
Journal ArticleDOI
Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication : A multicenter randomized trial
TL;DR: Seven- and 10-day rabeprazole-based triple therapies seem equally efficient in peptic ulcer patients and in contrast, 7-day therapy is significantly less effective in nonulcer dyspepsia patients.
Journal ArticleDOI
Meta-analysis: proton pump inhibitors vs. H2-receptor antagonists: their efficacy with antibiotics in helicobacter pylori eradication
Javier P. Gisbert,Sam Khorrami,Xavier Calvet,Rafael Gabriel,Fernando Carballo,José María Pajares +5 more
TL;DR: It is unknown whether proton pump inhibitors are superior to H2‐receptor antagonists in Helicobacter pylori eradication regimens and whether these drugs should be placed in combination with other chemotherapy regimens.
Journal ArticleDOI
Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry.
María Chaparro,Ana Garre,Elena Ricart,Marisa Iborra,Francisco Mesonero,Isabel Vera,Sabino Riestra,Valle García-Sánchez,M Luisa De Castro,A Martín-Cardona,Xavier Aldeguer,Miguel Minguez,Manuel Barreiro de-Acosta,Montserrat Rivero,Fernando Muñoz,Montserrat Andreu,Ana Bargalló,C González-Muñoza,José Lázaro Pérez Calle,M F García-Sepulcre,Fernando Bermejo,José María Huguet,José Luis Cabriada,Ana Gutiérrez,Míriam Mañosa,Albert Villoria,Ana Yaiza Carbajo,Rufo Lorente,Santiago García-López,M Piqueras,E Hinojosa,C Arajol,Beatriz Sicilia,Ana Macho Conesa,E Sainz,Pedro Almela,Jordina Llaó,Óscar Roncero,Patricia Camo,Carlos Taxonera,Manuel Van Domselaar,R. Pajares,Jesús Legido,Rosa Eva Madrigal,Alfredo J. Lucendo,Guillermo Alcain,Eugeni Domènech,Javier P. Gisbert +47 more
TL;DR: Effectiveness of vedolizumab in real world clinical practice is unknown and the mechanism of action is unknown.